Cardiology – Medxy AI

Expectant Management Improves Early Survival Without Increasing BPD: Results from the PDA Randomized Clinical Trial

By MedXY 12/12/2025

In extremely preterm infants with a protocol-defined PDA, expectant management yielded similar rates of death or BPD at 36 weeks’ postmenstrual age but significantly higher survival compared with active pharmacologic closure.

Cardiology Critical Care news

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT

By MedXY 12/12/2025

A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarkers of gut, renal, hepatic injury or inflammation.

Cardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial

By MedXY 12/12/2025

In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, providing no net clinical benefit versus anticoagulant monotherapy.

Cardiology Critical Care news

VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock

By MedXY 12/09/2025

A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.

Cardiology Critical Care news

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial

By MedXY 12/09/2025

In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.

Cardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

By MedXY 12/07/2025

In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding compared with anticoagulant monotherapy.

Cardiology Nephrology news

Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns

By MedXY 12/06/2025

A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active treatment groups.

Cardiology news

Stepping Down Antihypertensives in Frail Nursing-Home Residents Did Not Reduce Mortality: Results from the RETREAT-FRAIL Trial

By MedXY 12/06/2025

In the RETREAT-FRAIL randomized trial of nursing-home residents ≥80 years with systolic BP <130 mm Hg, a protocolized step-down of antihypertensive drugs reduced medication burden and raised systolic BP modestly but did not change all-cause mortality or adverse-event rates over ~3 years.

Cardiology news

Early Aspirin Withdrawal After PCI in ACS: Less Bleeding but Not Clearly Safe — Lessons from the NEO-MINDSET Trial

By MedXY 12/06/2025

In patients with acute coronary syndromes treated with PCI, stopping aspirin within 4 days and continuing potent P2Y12 inhibitor monotherapy reduced bleeding but did not meet noninferiority for ischemic events versus 12‑month DAPT; stent thrombosis was numerically higher.

Cardiology news

Stopping Aspirin After 1 Month Post‑PCI in Low‑Risk AMI: P2Y12 Monotherapy Is Noninferior and Bleeding‑Sparing

By MedXY 12/06/2025

In low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.

Cardiology news

Early Aspirin Withdrawal after PCI in Low‑Risk MI: P2Y12‑Inhibitor Monotherapy Noninferior and Significantly Less Bleeding

By MedXY 12/06/2025

In low‑risk acute MI patients with early complete revascularization and 1 month of uneventful DAPT, stopping aspirin and continuing P2Y12‑inhibitor monotherapy was noninferior for ischemic outcomes and cut clinically relevant bleeding nearly in half.

Cardiology Diabetes & Endocrinology news

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

By MedXY 12/05/2025

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus placebo in adults with obesity and prediabetes.

AI Cardiology Clinical Updates news

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

By MedXY 12/05/2025

This review evaluates AI algorithms predicting heart failure risk from noisy single-lead ECGs, synthesizing evidence from large multinational cohorts, highlighting improved risk stratification with AI-ECG models beyond traditional clinical scores.

Cardiology Emergency Medicine news

ED-Delivered Education Plus mHealth Lowers Systolic BP — TOUCHED Trial Shows a Modest but Meaningful 4.9 mm Hg Reduction at 6 Months

By MedXY 12/05/2025

The TOUCHED randomized trial found that an ED-initiated education plus mHealth and pharmacist/APRN consultation reduced systolic blood pressure by 4.9 mm Hg at 6 months versus usual care in patients discharged with elevated BP.

Cardiology news

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

By MedXY 12/04/2025

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality.

Cardiology news

OCT-Guided PCI Achieves Greater Stent Expansion Than Angiography in Calcified Lesions: Findings from the CALIPSO Randomized Trial

By MedXY 12/04/2025

In CALIPSO, OCT-guided PCI using predefined algorithms produced larger minimal stent area than angiography-guided PCI for moderate-to-severe calcified coronary lesions, with more targeted use of intravascular lithotripsy and no excess periprocedural safety signals.

Cardiology news

Unlocking Echocardiograms to Treat Undiagnosed Hypertension — The NOTIFY‑LVH Randomized Trial

By MedXY 12/03/2025

A centralized notification and support pathway using prior echocardiographic LVH increased antihypertensive initiation and new hypertension diagnoses versus usual care in a pragmatic randomized trial.

Cardiology Family Medicine & Nutrition news

EAT‑Lancet Diet and Recurrent Cardiovascular Events: Lower Stroke Risk and a Signal for Myocardial Infarction in Patients with Established CVD

By MedXY 12/03/2025

Two cohort analyses suggest greater adherence to the EAT‑Lancet diet is linked with lower recurrent non‑fatal vascular events—notably stroke—and that education and sex modify long‑term cardioprotective benefits of this sustainable, plant‑forward pattern.

Cardiology news Radiology

Anatomic First or Invasive Angiography First? DISCHARGE Shows No QOL Advantage for CT over ICA in Stable Chest Pain

By MedXY 12/03/2025

In the DISCHARGE randomized trial prespecified secondary analysis, CT-first and ICA-first strategies produced similar long-term quality-of-life and angina outcomes in intermediate-risk stable chest pain patients over a median 3.5 years; important sex differences persisted.

Cardiology Nephrology news

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

By MedXY 12/03/2025

The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, and recent heart failure worsening.